The N°1, healthy, rich in learning webinar about claims
Is your product a No. 1 seller? Good for your health or rich in fiber? Does it contain no parabens? Do you want to shout it loudly from the rooftops or at least on your packaging?
During this webinar, you will get an overview of the principles that need to be respected in order to claim your products legally. Our experts will discuss the rules for No. 1 claims, cosmetic claims and health and nutrition claims, and will give you an overview of the most important issues as well as practical guidelines.
This webinar has been awarded one point of continuous education by the Institut des Juristes d’Entreprise / Instituut voor Bedrijfsjuristen.
We hope to see you online on 14 March, from 13:30 to 14:30!
Recommended articles
Category Captains beware!: Belgian competition authority fines Category Management of OTC medicines
On 24 April 2025, the Belgian Competition Authority (BCA) announced a landmark decision imposing fines totaling over €11.2 million on three major pharmaceutical companies for their involvement in a long-running anti-competitive arrangement concerning the placement of over-the-counter (OTC) medicines in Belgian pharmacies..
Read on
The new Belgian government’s public health policy: 10 key take-aways for pharma policy
The new Belgian federal government has outlined its vision for public health in a policy paper under the slogan “More money for health, more health for our money”. Public health is a high-priority sector with a significant budget, and the policy paper introduces several key measures that will shape the pharmaceutical industry in the coming years. For pharma companies operating in Belgium, these developments bring both new regulatory challenges and strategic opportunities. Here is a focused analysis of ten key changes and their potential impact on the pharma industry.
Read on
CJEU’s DocMorris Ruling: where is the line for pharmaceutical advertising?
The intersection of pharmaceutical advertising, consumer protection, and internal market freedoms remains a complex legal battleground within the EU. In Apothekerkammer Nordrhein v. DocMorris NV (C-517/23), the Court of Justice of the European Union (CJEU) revisited the meaning of ‘advertising of medicinal products’, clarifying how far national restrictions on pharmaceutical advertisements can go under EU pharmaceutical law and internal market principles.
Read on